APR 16, 2020 9:00 AM PDT

Visualize more biomarkers and extract more insights: Moving from single marker IHC to multiplex IF

Sponsored by: Ultivue
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Associate Scientist, Cancer Genomics Research Laboratory (CGR) Division of Cancer Epidemiology and Genetics, NCI, FNLCR Leidos Biomedical Research
    Biography
      Scott is an associate scientist in the Molecular and Digital Pathology Laboratory for Leidos Biomedical Inc. The group primarily supports the Division of Cancer Epidemiology and Genetics (DCEG) of the NCI with all histopathology applications from tissue preparation though staining, imaging, and analysis. He started his career in a veterinary histopathology lab where he established digital imaging and analysis applications for preclinical work in mice and rats. Afterwards he worked with a pharmacodynamics group developing slide-based assays for phase 0 clinical trials focusing on standardizing multiplex immunofluorescent acquisition and analysis of tissue and circulating tumor cells. Scott has worked in the field for over 17 years bridging experience from the histology wet lab with digital imaging, automation, and analysis.
    • Associate Director, Biomarker Strategy & Applications, Ultivue
      Biography
        Dr. Patel is the Associate Director of Biomarker Strategy & Applications at Ultivue. Prior to joining Ultivue, Dr. Patel was a Product Manager at PerkinElmer for the Quantitative Pathology Solutions group where he managed their multiplex IHC portfolio. He is a trained immunologist and has focused his professional career on developing reagent-driven solutions for high-definition multiplex biological imaging in situ and creating innovative biomarker strategies within the fields of immuno-oncology and immuno-therapy research. Over the course of his career, Dr. Patel has worked with a variety of multiplex reagents, instruments, and bioinformatics tools. He earned his PhD from the University of Massachusetts, Amherst in Microbiology, focusing on Infectious Diseases & Immunology.

      Abstract
      DATE:  April 16, 2020
      TIME:   9:00am PT, 12:00pm ET
       
      There is an increasing need to evaluate and understand unique phenotypes and mechanisms of action within the tissue tumor microenvironment. Conventional assays such as chromogenic immunohistochemistry (IHC) allow researchers to rapidly evaluate biomarker expression and staining patterns. Chromogenic IHC is often limited to single-marker same-slide staining, thus the need to stain multiple serial sections. This leads to a lack of proper cell phenotyping and spatial relationship mapping. Ultivue’s InSituPlex® technology enables pathology scientists to perform an in depth investigation of multiple markers (up to 8) on a single tissue section allowing for multi-marker cell phenotyping at a high throughput rate compared to other multiplex immunofluorescence (IF) techniques.
       
      In this webinar, Scott Lawrence of Cancer Genetics Research Laboratory will share how his lab, using InSituPlex technology, is transitioning single-marker IHC assays to comprehensive multiplex immunofluorescence assays in order to gain more insights per sample.
       
      Learning Objectives:
      • Introduction to the InSituPlex® technology
      • Understanding of the UltiMapper™ kit portfolio and assay workflow
      • Learn the benefits and setbacks of using chromogenic IHC and multiplex IF
       
       
      Webinars will be available for unlimited on-demand viewing after live event.
       
      LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

       


      Show Resources
      You May Also Like
      OCT 08, 2020 7:00 AM PDT
      C.E. CREDITS
      OCT 08, 2020 7:00 AM PDT
      DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
      AUG 25, 2020 8:00 AM PDT
      C.E. CREDITS
      AUG 25, 2020 8:00 AM PDT
      DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
      NOV 18, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      NOV 16, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      SEP 10, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 10, 2020 9:00 AM PDT
      Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
      OCT 29, 2020 6:00 AM PDT
      C.E. CREDITS
      OCT 29, 2020 6:00 AM PDT
      Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
      Loading Comments...
      Show Resources
      Attendees
      • See more